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Abstract
Veno-occlusive disease (VOD) is a complication arising from the toxicity of conditioning regimens that have a significant impact on the 
survival of patients who undergo stem cell transplantation. There are several known risk factors for developing VOD and their assessment 
before the start of conditioning regimens could improve the quality of care. Equally important are early identification of signs and symptoms 
ascribable to VOD, rapid diagnosis, and timely adjustment of support therapy and treatment. Nurses have a fundamental role at the stages 
of assessment and monitoring for signs and symptoms; therefore, they should have documented skills and training. The literature defines 
nurses’ areas of competence in managing VOD, but in the actual clinical practice, this is not so clear. Moreover, there is an intrinsic diffi-
culty in managing VOD due to its rapid and often dramatic evolution, together with a lack of care tools to guide nurses. Through a complex 
evidence-based process, the Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO), cellule staminali emopoietiche e terapia cellulare 
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nursing board has developed an operational flowchart and a dynamic monitoring tool applicable to haematopoietic stem cell transplantation 
patients, whether they develop this complication or not.
Keywords: veno-occlusive disease, stem cell transplantation, nurse management, assessment, monitoring
Background
Veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS) is a potentially life-threatening complication affecting patients 
undergoing haematopoietic stem cell transplantation (HSCT) [1]. Conditioning regimens prior to HSCT favour endothelial cell activation, 
causing damage to sinusoids and liver cells [2]. Accumulation of cells and cell degradation products in the perisinusoidal space leads to an 
increased inflammation of the sinusoids, restricting their lumen through a thrombotic process until their complete obstruction. This rapidly 
results in slowing of intrahepatic blood flow that can go as far as inversion of the portal flow with compromise of liver function [1–3].
VOD has an average prevalence among patients undergoing HSCT of approximately 13.7%, [3] with a mortality of severe forms that reaches 
80% of cases [4]. It is usually observed from 35 to 45 days after transplant, but it can also occur a long time afterwards. It is associated with 
an increase in HSCT-related costs [5–6] because of the need for intensive care.
There are several risk factors for the development of VOD that plays a role in increasing its incidence and impacting mortality [9–10], mak-
ing it necessary to pay particular attention during patient assessment and monitoring activities [11–12].
Patient-related risk factors are as follows: liver disease, elevated transaminases, age, malignant pathologies, failure to achieve remission, 
history of hepatic irradiation, and genetic predisposition. Therapy-related risk factors are as follows: type of HSCT, intensity of conditioning, 
duration and type of drugs used and their hepatotoxicity, donor type and origin of stem cells, the presence of fever during conditioning, 
HSCT history, abdominal irradiation, and previous treatments with gemtuzumab [8–9]. 
VOD is diagnosed on the basis of clinical observation, using the Modified Seattle [15] and Baltimore criteria [16].
However, signs and symptoms vary and can be the expression of many other pathological conditions, which make differential diagnosis 
necessary [9,17,18]. There are many conditions that can mimic VOD, including acute hepatic graft-versus-host disease, fungal and viral 
infections, cholangitis, fatty liver disease, drug toxicity, and cholestasis. The differential diagnosis may present a challenge for the clinician, 
often with delayed treatment. Therefore, the early identification of signs of VOD is essential for setting up adequate treatment.
At the early stage, VOD is characterised by a hepatorenal syndrome, with rapid weight gain, ascites, hepatomegaly, jaundice, pain in the 
right upper quadrant, and thrombocytopenia [7–8] often followed by multiorgan failure (MOF) at the later stage. 
VOD can be classified as follows on the basis of severity [18–19]:
• Mild VOD is defined as a pathology that meets the diagnostic criteria but does not require treatment for excess fluid or drugs for liver 
pain, the course of which is usually self-limiting;
• moderate VOD is a pathology with evidence of liver damage that requires treatment for excess fluid or drugs for liver pain, but which 
is fully resolved;
• severe VOD is defined as a pathology that causes death or is not resolved within 100 days following HSCT.
The above classification of VOD derives from retrospective studies and therefore is not useful from the prognostic point of view; some 
attempts, in this direction, were made by Chao [20] and Carreras [11] in 2014, but a strong consensus has yet to be found.
Progressive VOD may rapidly lead to MOF [15], with hepatomegaly and weight gain, progressive appearance of pulmonary and pleural 
infiltrates, diffuse oedema, cardiac insufficiency, renal insufficiency, ascites, bleeding, and neurological symptoms. Recovery from such a 
condition is very difficult [6].
Management strategies currently consist predominantly of a supporting therapy that takes into account the various organs involved and 
fluid and electrolyte balances remains one of the key elements in the phases of prevention and treatment of VOD [21].
Therapy with a combination of heparin and recombinant tissue plasminogen activator has shown responses in 30% of patients, but it is 
associated with an increased risk of haemorrhage and poor overall survival [17, 22–23]. Currently, the only drug approved by the European 
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Medicines Agency (EMA) for the treatment of severe VOD is defibrotide [24]. Defibrotide has also been used in prevention with encourag-
ing results [25, 26, 27, 28], although high-quality randomised, controlled studies are needed to define the ideal prophylactic regimen [29].
Rationale
Every nurse working in a transplant programme (TP) should developed distinctive skills that exert a significant influence in terms of 
improving clinical outcomes, impacting on the quality and cost-effectiveness of treatments, and adding value to the nurse’s role itself in 
the transplant context [30].
Nurses are indeed involved during assessment and management of patients presenting with VOD, and a nurse trained to recognise signs 
and symptoms of VOD will certainly be able to contribute to early diagnosis of this complication [31–32]. The nurse role is fundamental 
during patient monitoring in order to report changes in weight, to assess jaundice, nutritional matters, and abdominal girth [32]. The nurse 
should be capable of correctly monitoring fluid and electrolyte balances, evaluating bleeding and assessing pain. Management of patients 
with VOD often requires fluid intake restriction, a personalised diet or fasting and patient mobilisation. It is also necessary to administer 
analgesics, blood products, electrolytes, and drugs, and to support the patient from the psychological point of view [17–18].
Joint Accreditation Committee-ISCT Europe (JACIE) [33] accreditation is a voluntary accreditation of excellence. JACIE quality standards 
require training and VOD management-specific skills only for physicians, although it is clear that the role of nurses is crucial for diagnosis 
and monitoring [18–34].
Different published studies [12, 17, 18, 34] describe the most important parameters to be assessed - suggesting the need of close monitoring, 
particularly in patients with severe VOD. However, to the best of our knowledge, this is the first report that provides a useful tool for clinical 
practice, differentiating VOD management on the basis of levels of risk and VOD evaluation. The aim of this work is to describe the develop-
ment of a new tool ‘VOD early identification and management’ by the Gruppo Italiano Trapianto di Midollo Osseo Nursing Group (GITMO NG).
Materials and Methods
The tool was created using the following three different routes: 
• Creation of a nurse expert panel (NEP)
• Critical analysis of the literature and standard operating procedures (SOPs)
• Analysis of daily clinical practice in TPs (multicentre survey) 
During the 2014 GITMO congress, the nurse board formed an expert panel (NEP), made up of professionals with expertise in stem cell 
transplantation from various Italian TPs. The NEP consisted of 10 nurses working in paediatric TPs and eight nurses working in adult TPs, 
including three specialist paediatric nurses, two research nurses, six head nurses, and one quality manager nurse. The mean age of the 
group was 42 years (28–57); the average length of service in TP of 14.8 years (6–28).
A literature search was conducted on PubMed, Embase, Cinhal, Cochrane Library, National Guideline Clearinghouse, the National Insti-
tutes of Health, and afterwards, the group performed a critical review of published studies. In addition, the group reviewed SOPs in the use 
in TPs and performed an audit of clinical competencies and activities to assess and monitor HSCT patients. 
At the same time, a survey questionnaire was developed and shared among all Italian TPs, with the aim of taking a snapshot of the reality 
of clinical practice on management of VOD in patients undergoing allogeneic HSCT. The survey consisted of 43 questions, with single or 
multiple responses, addressing organisational and structural topics, monitoring of patients undergoing HSCT, nursing skills and knowledge 
related to VOD management (assessment, diagnosis, prevention, treatment, care). The survey was shared with all the transplant centres 
in the GITMO network on a web platform, and data were analysed by frequency using SPSS 20.
The results of the literature and SOPs reviews, the audit and the survey were shared and discussed within the NEP in some structured 
meetings.
The NEP evaluated the results and identified the key points for the development of the tool to assess and monitor patients throughout their 
transplant journey. Then, the NEP produced a pathway flow chart.
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Results
Results of the multicentre survey
‘The nurse in HSCT: monitoring hepatic complications and management of sinusoidal obstruction syndrome (SOS) and veno-occlusive dis-
ease (VOD)’.
The survey conducted within the GITMO network was addressed to centres that carry out allogeneic HSCT. The main results revealed a 
somewhat mixed approach to monitoring across the various TPs; the Seattle and Baltimore diagnostic criteria are not often used by nurses, 
there appears to be a substantial lack of specific tools and patient monitoring is done through standard procedures for the general assess-
ment of patients after transplantation. TPs characteristics are given in Table 1.
Standard monitoring
The vast majority of TPs (95%) have monitoring protocols or specific checklists (82.5%). The parameters that are assessed at least daily 
(1 to 3 times per day) in all centres are classically: blood pressure, heart rate, temperature, weight, and pain. There are wide differences 
in the approach regarding the assessment of respiratory rate, oximetry, and diuresis. Figure 1 shows the main results related to standard 
monitoring practice in TPs. Only 40% of centres report written documentation of alert values derived from monitoring data. For the pur-
poses of this paper, we are able to observe that only 10% of centres put daily measurement of abdominal girth as a standard monitoring 
parameter and that no centres take into account any other type of anthropometrical measurement (e.g., deltoid). 
All the centres check fluid and electrolyte balances, but with widely differing policies (Figure 1). Ninety-five per cent of transplant pro-
grammes do not have nurses trained in abdominal palpation of patients; in only 5% of TPs abdominal palpation is also carried out by nurses. 
More than 90% of TPs carry out laboratory tests more than 2–3 times a week. In this context, we also noted that parameters useful in the 
diagnosis of VOD are not recorded in a structured and systematic manner: aldolase is monitored on a routine basis only in 20% of TPs, and 
ornithine transcarbamylase only in 5%. Figure 2 shows detailed data on the standard monitoring of biochemical parameters.
Nurse training
In 40% of transplant programmes, nurses had the opportunity to receive training in hepatic complications of HSCT within the last two years, but 
the participation rate of nurses in training events was lower than 60% in 68.8% of TPs.
Table 1. Characteristics of transplant centres.
Responses (%)
Number of respondents 40/80 (50.0)
Patient group
• Adults
• Paediatrics
• Both (adults and paediatrics)
24 (60.0)
11 (27.5)
5 (12.5)
Centre organisation
• SCT unit
• SCT unit within Haematology unit
17 (42.5)
23 (57.5)
Transplant type performed
• Autologous – Sibling
• Autologous – Allogeneic – MUD
• All transplant therapies
2 (5.0)
5 (12.5
33 (82.5)
SCT: stem cell transplant; MUD: matched unrelated donor
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Figure 1. Standard nurse assessment.
Figure 2. Standard monitoring of biochemical parameters.
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VOD patients management
It was found that pre-HSCT risk assessment for hepatic complications is not carried out in 15.4% of TPs. The overall risk assessment is 
usually carried out by physicians without the presence of a nurse (85%) and in 33.3% of TPs nurses are not informed of the results of the 
pre-HSCT risk assessment.
In 82.5% of TPs, SOPs for the diagnosis of VOD are present and in 90% of centres the modified Seattle and Baltimore criteria are used by 
healthcare professionals. However, in 82.5% of TPs, the Seattle and Baltimore diagnostic criteria are not used by nurses. There are SOPs 
for the prevention and the treatment of VOD in 55% and 82.5% of TPs, respectively. Nurses are familiar with the differential diagnostic 
pathway (72.5% of TPs), the strategies adopted to prevent VOD (65%), and therapeutic strategies (80%). 
Despite this, availability of SOPs for care (42.5%) and monitoring (52.5%) of patients with VOD is scattered in Italian TPs.
The most widely used techniques for differential diagnosis remain hepatic vessel Doppler (95%), hepatic tomography (30%) and levels of 
plasminogen activator inhibitor-1 (30%). Only 7.5% of TPs use transjugular biopsy to diagnose VOD. 
For prevention strategies, our results showed a certain amount of variation, with 35% of TPs not undertaking pharmacological prevention, 
and the remaining centres using various strategies, among which the most representative are ursodeoxycholic acid, supportive therapy, 
and defibrotide. 
Supportive therapy and defibrotide seem to be the therapeutic strategies universally used.
Results from the NEP
The NEP, through the literature analysis and sharing of procedures and experiences, identified three key areas for the assessment and 
monitoring of patients, corresponding to the clinical phases of the transplant journey: pre-conditioning period, during conditioning and post-
conditioning. To allow for applicability in the various treatment settings, essential parameters were identified and agreed by the group. A full 
account of nursing activities in the various degrees of VOD is described by Eisenberg et al [18].
Pre-conditioning (or assessment phase)
Generally, before admission, an assessment process is put in place through a multidisciplinary approach; nurses should be involved and 
should be informed about results of risk assessment. The group agreed that all patients undergoing HSCT should be considered at risk of 
VOD, whereby the NEP decided to identify two risk levels: ‘standard risk’ to be assigned to all patients without major risk factors for devel-
oping severe VOD, such as the presence of active and previous pathologies of the liver (fibrosis, cirrhosis, fatty liver disease, previous 
hepatitis), high transaminase levels also in the absence of other clinical signs of level disease, allogeneic HSCT, myeloablative condition-
ing, the use of drugs such as busulfan, the use of total body irradiation (TBI), alloreactivity, previous hepatotoxic treatments (gemtuzumab) 
[11–17]. The expert panel defined at ‘increased’ risk patients in whom at least one of the factors listed previously is present or a combination 
of other risk factors such as age and sex (elderly women are at greater risk), type and status of disease, genetic susceptibility, development 
of fever during conditioning, hepatotoxic treatments (vancomycin, acyclovir). At this phase, it is important that nurses perform anamnesis 
and assessment by collecting information and checking parameters in the areas indicated in Table 2 (part A). Results of the nursing assess-
ment process should be shared within the team, recorded in patient records and reviewed, if necessary, before beginning conditioning. 
Implementation of alert systems may be also useful in this setting.
During conditioning 
For this period, at this stage, the expert panel defined two monitoring protocols, as shown in Table 2 (part A), of differing intensity according 
to the level of risk established at the previous phase. 
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After conditioning
During this period, nurses should carry out systematic assessment using Seattle (modified) and Baltimore criteria. If no change from base-
line values is detected, patient monitoring should be continued routinely. 
If on the basis of Seattle and Baltimore criteria a ‘Suspected VOD’ is define, physicians should be alerted to begin differential diagnosis 
procedures as soon as possible.
It is also necessary to make arrangements for the intensification of the monitoring process as indicated in Table 2 (part B), until the diagno-
sis is confirmed or ruled out, paying particular attention to the rate of progression of disease and multiple organ involvement.
If differential diagnosis confirms the presence of VOD, patient monitoring should be intensified (high-intensity monitoring protocol) until 
continuous monitoring of certain parameters is introduced, as indicated in Table 2 (part C).
Activities for intensive support in relation to any multiple organ components should be put in place and preparations made for a quick trans-
fer of the patient to intensive care (ICU). If VOD is not confirmed, care will continue in accordance with the clinical standards for whatever 
is present. The expert panel agreed that if the differential diagnosis is complex and/or it is not possible to have a diagnostic confirmation 
of VOD, faced with a rapid worsening of the patient’s signs and symptoms it is necessary to consider the patient critical and go ahead with 
high intensity monitoring and possible transfer of the patient to the ICU. 
Conclusions
Patient assessment and monitoring represent the mainstream of effective nursing support. It is fundamental to support these activities with 
specific tools, suited to the setting of care, in order to avoid situations where data and information are not appropriately recorded therefore 
producing a negative impact on the care process. In HSCT, the patient’s clinical conditions are extremely variable and consequently require 
tools capable of capturing all the possible changes that can have an impact on the patient’s health. 
The early diagnosis and management of VOD is complex. It is essential that standardised, evidence-based practice procedures, which are 
ultimately based on practical needs and on clinical experience, are not perceived only as theoretical models but instead as widely accepted 
daily practices.
Eisenberg’s suggestions [18] for appropriate nursing interventions to support the various organs and tissues and the psychological state 
of patients with VOD, were very helpful in this respect. Despite this, an unequivocal guidance for VOD-related nursing problems is not 
available. This work is aimed at defining dynamic and practice guidelines taking into account the evolution of the patient’s conditions and 
the need of a practical approach in the transplant setting. In conclusion, the NEP on behalf of the GITMO NG is proposing a practical 
and dynamic flow chart that could be useful for the assessment and monitoring of the patient clinical course (Figure 3). This tool is easily 
manageable and could be immediately adopted in daily practice. In view of the innovative nature of this tool, a prospective clinical evalu-
ation is warranted. 
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Table 2. Monitoring protocol.
Part A. Case history/Pre-conditioning nursing assessment
•  Take vital signs: arterial pressure, heart rate, respiratory rate, body temperature, oxygen 
saturation
• Measure weight (define 5% threshold value)
•  Abdominal assessment (visual and by palpation), in particular of the RUQ: record spontaneous 
and induced pain (Blumberg), record abdominal circumference, abdominal volume, the  
presence of collateral circles and/or spiders, tractability, percussion (obtuseness), the  
assessment of hepatic RIMA and dimensions of the liver, assessment of hepatic consistency
•  Assessment of skin: erythema, lesions, haemorrhages, dyschromia (jaundice)
• Assessment of sclera: microhaemorrhages, jaundice
•  Consider blood test values: total and fractionated bilirubin, transaminases, LDH,  
electrolytes (Na, K)
•  Details of patient’s clinical history, personal habits (diet, smoking, alcohol) and social  
background
Assignment of standard or increased risk level
Alert for the confirmation of risk level on admission
Standard risk Increased risk
At least once a day 
• Weight
• Abdominal circumference
• Abdominal pain and RUQ pain
•  Objective examination of skin, sclera, abdo-
men (palpation)
• Fluid balance
At least twice a week and whenever signifi-
cant variations in clinical signs are observed 
•  Measurement of bilirubin, transaminases, 
sodium, potassium, coagulation parameters
At least twice a day 
• Weight
• State of awareness
• Abdominal circumference
• Abdominal pain and RUQ pain
•  Objective examination of skin, sclera,  
abdomen (palpation)
• Fluid balance
Between three times a week to every  
day whenever significant variations in  
clinical signs are observed
•  Measurement of bilirubin, transaminases, 
sodium, potassium, coagulation parameters
Report even small changes in clinical  
condition in a timely fashion
Educate patient and CGs in timely  
communication
Report even small changes in clinical  
condition in a timely fashion
Educate patient and CGs in timely  
communication
Part B. Patients who meet the modified Seattle and Baltimore criteria: Intensified  
Monitoring Protocol
At least twice a day
• State of awareness
•  Abdominal circumference
Full objective examination of 
abdomen, sclera, skin, and 
mucosae
At least three times a day
• Weight
• Pain in RUQ
Monitor for appearance of 
signs of haemorrhage (skin, 
sclera, mucosae
At least four times a day
•  Fluid and electrolyte  
balance
• Oxygen saturation
Vital signs: arterial pressure, 
heart and respiratory rate, 
body temperature
• Foresee the need for continuous monitoring of parameters
•  Intensify monitoring of blood tests: fractionated bilirubin, transaminases, coagulation  
parameters, sodium, potassium, and other tests prescribed by the doctor 
• Provide psychological support for patient and family members or CGs
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Table 2. Continued.
Part C. Patients with a diagnosis of VOD: High-intensity monitoring protocol
At least twice a day
• Abdominal circumference
•  Full objective examination of 
abdomen, sclera, skin and 
mucosae
At least three times a day
• Weight
• Pain in RUQ
•  Monitor for the appearance 
of signs of haemorrhage 
(skin, sclera, mucosae)
At least four times a day
•  Fluid and electrolyte  
balance
Consider patient as critical
•  Continuous monitoring of vital signs using monitors: arterial pressure, heart rate,  
respiratory rate, body temperature, oxygen saturation.
• Ventilatory support if necessary: oxygen therapy or non-invasive ventilation
• Ensure drastic reduction in fluid intake 
• Ensure appropriate number of vascular access points 
• Frequently monitor diuresis, possible use of bladder catheter with urometer
• Evaluate performance status and state of awareness 
• Monitor for MOF: cardiac, respiratory, and renal function
• Provide psychological support for patient and family members or CGs
• Make arrangements for rapid transfer to CU
RUQ: right upper quadrant; LDH: lactic dehydrogenase; CGs: care givers; MOF: multiple organ failure; 
ICU: intensive care unit.
Figure 3. Pathway flow chart.
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